Search results
The top pharmaceutical companies by R&D expenditure
Pharmaceutical Technology via Yahoo Finance· 1 hour agoThis analysed R&D investments were in the form of strategic acquisitions to expand a company’s prowess in a particular area or by in-licensing drug...
Cantor Fitzgerald Brokers Boost Earnings Estimates for Merck & Co., Inc. (NYSE:MRK)
ETF DAILY NEWS· 2 days agoMerck & Co., Inc. (NYSE:MRK – Free Report) – Equities research analysts at Cantor Fitzgerald increased their FY2024 earnings per share (EPS) estimates for ...
Merck's KEYTRUDA shows survival benefit in gastric cancer trial By Investing.com
Investing.com· 14 hours agoMerck & Co., Inc., a leading pharmaceutical company, announced positive results from the Phase 3...
Merck & Co., Inc. (NYSE:MRK) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 2 days agoMerck & Co., Inc. (NYSE:MRK) Q1 2024 Earnings Call Transcript April 25, 2024 Merck & Co., Inc. beats...
Merck Raises Forecast as Sales of Its Cancer Immune Therapy Soar
Bloomberg· 7 days agoMerck & Co. raised its annual profit and revenue forecast as the blockbuster cancer drug Keytruda...
Merck raises 2024 profit forecast on strong cancer, HPV drugs sales
KFGO· 7 days agoBy Patrick Wingrove (Reuters) - Merck & Co on Thursday raised its annual profit and revenue forecast...
Merck reports promising V116 vaccine trial results By Investing.com
Investing.com· 3 days agoMerck & Co. (NYSE: MRK) has presented new data from its Phase 3 STRIDE-10 trial of V116, an...
Merck & Co., Inc. (NYSE:MRK) Just Released Its First-Quarter Earnings: Here's What Analysts Think
Simply Wall St. via Yahoo Finance· 5 days agoMerck & Co., Inc. (NYSE:MRK) just released its quarterly report and things are looking bullish. The...
Merck jumps on profit beat as Bristol Myers Squibb slips to a loss
Proactive Investors· 7 days agoMerck & Co Inc (NYSE:MRK, ETR:6MK), the pharmaceutical firm, saw its shares tick 3.5% higher after...
Merck Raises 2024 Profit Forecast on Strong Sales of Cancer Drug Keytruda
US News & World Report· 7 days agoKeytruda, the world's top selling drug in 2023, has been Merck's key revenue driver over the past few years and is expected to top $30 billion in sales by 2026 before losing exclusivity toward ...